TLDR
- IBM has finalized a $1 billion R&D grant from the U.S. Commerce Department to build Anderon, America’s first quantum chip foundry.
- Anderon will operate as an IBM subsidiary, located in upstate New York, using 300-millimeter wafer technology.
- IBM has pledged an additional $1 billion of its own to support Anderon, with Mukesh Kare named as CEO.
- IBM’s most recent quarterly EPS came in at $2.93, matching estimates, though revenue of $17.16 billion missed forecasts of $17.46 billion.
- Analysts hold a consensus “Moderate Buy” on IBM with an average price target of $265.16; the stock opened at $248.39 on Wednesday.
IBM stock dipped 0.3% in early trading Wednesday as the company formally sealed a $1 billion deal with the U.S. Commerce Department to build the country’s first quantum chip foundry.
International Business Machines Corporation, IBM
The facility, called Anderon, is structured as a research-and-development grant under the 2022 Chips and Science Act. IBM is also putting up $1 billion of its own money to back the project.
Anderon will operate as an IBM subsidiary out of upstate New York. The 300-millimeter wafer foundry will serve IBM as one of several customers, with interest from companies like D-Wave already confirmed.
Mukesh Kare, currently IBM’s semiconductor division general manager, has been named Anderon’s CEO. He said the facility would move quantum computing “from research breakthroughs to real-world impact.”
IBM Research chief Jay Gambetta had said back in May the company needed a “reliable baseline fab” to design a new quantum processor every year. Anderon is that facility.
Part of a Broader Federal Push
The Anderon deal is part of a wider $2 billion federal funding package. Last week, Rigetti Computing, D-Wave Quantum, and Quantinuum each received $100 million deals from the Commerce Department. Chipmaker GlobalFoundries also landed a $375 million pact to build out domestic manufacturing.
The government’s push into quantum mirrors its earlier involvement in semiconductors and critical minerals. DARPA is separately running a validation program aimed at building an error-corrected, utility-scale quantum computer by 2033.
IBM also has a target on its own books: delivering a fault-tolerant quantum computer to a national laboratory by 2028, though that goal remains uncertain.
IBM Fundamentals and Analyst View
IBM opened at $248.39 on Wednesday. Its 50-day moving average sits at $234.72, and the 200-day average is $246.74. The stock’s 52-week range runs from $199.19 to $332.46.
The company’s most recent quarterly earnings hit $2.93 EPS, matching Wall Street’s estimate. Revenue came in at $17.16 billion, up 1.1% year over year, but short of the $17.46 billion forecast.
IBM pays a quarterly dividend of $1.69, representing a 2.7% annualized yield. The payout ratio stands at 59.98%.
Institutional investors own 58.96% of IBM. HighTower Advisors increased its stake by 27.8% in Q2, adding 372,987 shares to bring its total holding to 1.72 million, worth around $482.6 million.
On the other side, SVP Robert Thomas sold 25,000 shares on August 26th at $230.32, cutting his ownership by 34.34%. Insiders collectively hold just 0.27% of the stock.
Seventeen analysts rate IBM a Buy, ten say Hold, and one says Sell. The average price target is $265.16, with Bank of America setting the high end at $330.
IBM stock opened at $248.39 Wednesday, trading below the analyst consensus target as the Anderon announcement failed to move the needle in early trading.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.







